IDRx
idrx.com
Biotechnology
Vaccines
Health Care
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Salaries
Products
People
Growth
Offices
Financials
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Nextech InvestVia a fund
63 portfolio companies: Zymeworks, Vividion Therapeutics (Acquired), Zenith Therapeutics and 60 more
Andreessen HorowitzVia a fund
849 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
GSK Strikes Deal to Acquire IDRx for $1 Billion PharmExec
Under terms of the deal, GSK will also acquire IDRX-42, a tyrosine kinase inhibitor designed to treat both primary and secondary KIT mutations in patients with gastrointestinal stromal tumors.
Read more
Report
GSK to Buy IDRx for $1.15 Billion as Mergers and Acquisitions Pick Up Steam in 2025
IDRx is a clinical-stage company that develops intelligently designed precision therapies for treating gastrointestinal stromal tumors.
Read more
Report
Is GSK prepping a $1bn takeover bid for IDRx?
GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.
Read more
Report
IDRx Raises $120 Million To Transform Cancer Treatment With Precision Therapies
IDRx (a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies) announced the completion of an oversubscribed $120 million Series B Preferred Stock financing. This financing was led by RA
Read more
Report
IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST)
Read more
Report
Aiming to bring drug combos into earlier lines of cancer therapy, IDRx lands $122M
Taking inspiration from the success of drug cocktails that halt viral infections, startup IDRx aims to develop cancer drug combinations that stop tumor escape. The company, founded by serial entrepreneur Alexis Borisy, has set gastrointestinal stromal tum
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
London
United Kingdom
Regional office
Codes, standards and reports
200-500 est. staff
Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG
Financials
Total raised
$120M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2024 | $120M | Details |